Eli Lilly and Company $LLY Shares Sold by Groupe la Francaise

Groupe la Francaise cut its holdings in Eli Lilly and Company (NYSE:LLY) by 2.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 132,176 shares of the company’s stock after selling 3,566 shares during the period. Eli Lilly and Company comprises about 1.7% of Groupe la Francaise’s holdings, making the stock its 12th largest position. Groupe la Francaise’s holdings in Eli Lilly and Company were worth $120,988,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $25,000. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $30,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares during the last quarter. Finally, Dorato Capital Management acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $36,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 4.5%

LLY stock opened at $1,155.97 on Friday. The company has a 50 day moving average price of $1,151.01 and a two-hundred day moving average price of $1,043.41. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market capitalization of $1.09 trillion, a P/E ratio of 41.06, a PEG ratio of 1.50 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the prior year, the company posted $3.34 EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. As a group, sell-side analysts expect that Eli Lilly and Company will post 34.91 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of analyst reports. Barclays increased their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a report on Monday, May 4th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. The Goldman Sachs Group restated a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Finally, Royal Bank Of Canada boosted their target price on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research note on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Manufacturing expansion supports future demand. Lilly and Resilience are investing $750 million to expand U.S. production of diabetes and obesity medicines. The project is expected to add at least 400 jobs in West Chester, Ohio, and lift Resilience’s Ohio workforce above 1,400. Lilly says the investment is part of approximately $55 billion committed to U.S. manufacturing, helping address supply constraints and support growth. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
• Positive Sentiment: Retatrutide reaches a late-stage clinical milestone. Lilly completed a Phase 3 trial of retatrutide, its next-generation obesity and diabetes candidate. The completion sets up a potentially important catalyst when results are released, particularly because the drug could expand Lilly’s position in weight management and related cardiovascular markets. Lilly’s Retatrutide Trial Reaches Completion
• Positive Sentiment: Analyst coverage remains broadly favorable, with brokerages assigning a consensus “Moderate Buy” rating. Commentators also point to Lilly’s expanding drug pipeline beyond its current weight-loss products as a longer-term growth driver. Consensus Recommendation of Moderate Buy
• Neutral Sentiment: Lilly’s planned $2.8 billion acquisition of AtaiBeckley would broaden its pipeline into psychedelic-based treatments, but the deal also introduces development and integration risk and is not an immediate earnings catalyst. Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion
• Negative Sentiment: Erste Group Bank reduced its 2026 EPS forecast to $35.34 from $36.33, although the revised estimate remains above the broader consensus of $34.91. The adjustment may be weighing on sentiment while LLY trades at a premium valuation and near its 12-month high. Eli Lilly Analyst Estimate Update

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.